A phase iia randomized control trial of VEL015 (sodium selenate) in mild-moderate Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 54, Issue 1, 2016, Pages 223-232

  Malpas, Charles B ^a,b   Vivasha, Lucy ^a   Genc, Sila ^a,e   Saling, Michael M ^b,c,d   Desmond, Patricia ^a,e   Steward, Christopher ^a,e   Hicks, Rodney J ^a,i   Callahan, Jason ⁱ   Brodtmann, Amy ^d,f   Collins, Steven ^e,j   MacFarlane, Stephen ^g   Corcoran, Niall M ^e   Hovens, Christopher M ^e   Velakoulis, Dennis ^e,h   O'Brien, Terence J ^a,e  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c AUSTIN HEALTH   (Australia)

^d AUSTIN HOSPITAL   (Australia)

^e ROYAL MELBOURNE HOSPITAL   (Australia)

^f MONASH UNIVERSITY   (Australia)

^g Caulfield Hospital   (Australia)

^h Peter MacCallum Cancer Institute ^*  (Australia)

ⁱ PETER MACCALLUM CANCER CENTRE   (Australia)

^j ST VINCENT S HOSPITAL   (Australia)

more..

Author keywords

Alzheimer's disease; Clinical trial; Dementia; Sodium selenate

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; PLACEBO; SELENATE; TAU PROTEIN; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); MAPT PROTEIN, HUMAN; NEUROPROTECTIVE AGENT; PEPTIDE FRAGMENT; SELENIC ACID;

ADULT; AGED; ALZHEIMER DISEASE; ARTHRALGIA; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; DECREASED APPETITE; DETERIORATION; DIFFUSION WEIGHTED IMAGING; DISEASE COURSE; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEADACHE; HUMAN; INCIDENCE; LETHARGY; MALE; MULTICENTER STUDY; MUSCLE SPASM; MYALGIA; NAIL DISEASE; NAUSEA; NEUROIMAGING; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRESYNCOPE; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN PHOSPHORYLATION; PROTOCOL COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; RASH; CLINICAL TRIAL; COGNITION; DIAGNOSTIC IMAGING; DRUG EFFECTS; FOLLOW UP; MIDDLE AGED; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOMARKERS; COGNITION; DIFFUSION MAGNETIC RESONANCE IMAGING; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; PEPTIDE FRAGMENTS; POSITRON-EMISSION TOMOGRAPHY; SELENIC ACID; TAU PROTEINS; TREATMENT OUTCOME;

EID: 84984669520     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-160544     Document Type: Article

References (24)

1. Gong C, Iqbal K (2008) Hyperphosphorylation of microtubule-associated protein tau: A promising therapeutic target for Alzheimer disease. Curr Med Chem 15, 2321.
2. Goedert M, Jakes R, Qi Z, Wang J, Cohen P (1995) Protein phosphatase 2A is the major enzyme in brain that dephos-phorylates τ protein phosphorylated by proline-directed protein kinases or cyclic AMP-dependent protein kinase. J Neurochem 65, 2804-2807.
3. Gong C-X, Lidsky T, Wegiel J, Zuck L, Grundke-Iqbal I, Iqbal K (2000) Phosphorylation of microtubule-associated protein tau is regulated by protein phosphatase 2A in mammalian brain implications for neurofibrillary degeneration in Alzheimer's disease. J Biol Chem 275, 5535-5544.
4. van Eersel J, Ke YD, Liu X, Delerue F, Kril JJ, Götz J, Ittner LM (2010) Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer's diseasemodels. Proc Natl Acad Sci USA 107, 13888-13893.
5. Corcoran N, Hovens C, Michael M, Rosenthal M, Costello A (2010) Open-label, phase I dose-escalation study of sodium selenate, a novel activator of PP2A, in patients with castration-resistant prostate cancer. Br J Cancer 103, 462-468.
6. Jones NC, Nguyen T, Corcoran NM, Velakoulis D, Chen T, Grundy R, O'Brien TJ, Hovens CM (2012) Targeting hyperphosphorylated tau with sodium selenate suppresses seizures in rodent models. Neurobiol Dis 45, 897-901.
7. Shultz SR, Wright DK, Zheng P, Stuchbery R, Liu SJ, Sashindranath M, Medcalf RL, Johnston LA, Hovens CM, Jones NC, O'Brien TJ (2015) Sodium selenate reduces hyperphosphorylated tau and improves outcomes after traumatic brain injury. Brain 138, 1297-1313.
8. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-939.
9. Lezak MD, Howieson D, Loring D, Hannay H, Fischer J (2004) Neuropsychological Assessment, Oxford University Press, Oxford.
10. Cook M, Fish D, Shorvon D, Straughan K, Stevens J (1992) Hippocampal volumetric and morphometric studies in frontal and temporal lobe epilepsy. Brain 115, 1001-1015.
11. Reuter M, Fischl B (2011) Avoiding asymmetry-induced bias in longitudinal image processing. Neuroimage 57, 19-21.
12. Jenkinson M, Beckmann C, Behrens T, Woolrich M, Smith S (2012) FSL. Neuroimage 62, 782-790.
13. Bach M, Laun FB, Leemans A, Tax CM, Biessels GJ, Stieltjes B, Maier-Hein KH (2014) Methodological considerations on Tract-Based Spatial Statistics (TBSS). Neuroimage 100, 358-369.
14. Landau SM, Harvey D, Madison CM, Koeppe RA, Reiman EM, Foster NL, Weiner MW, Jagust WJ (2011) Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging 32, 1207-1218.
15. Bonett DG (2008) Confidence intervals for standardized linear contrasts of means. Psychol Method 13, 99.
16. Smith SM, Jenkinson M, Johansen-Berg H, Rueckert D, Nichols TE, Mackay CE, Watkins KE, Ciccarelli O, Cader MZ, Matthews PM (2006) Tract-based spatial statistics: Voxelwise analysis of multi-subject diffusion data. Neu-roimage 31, 1487-1505.
17. Smith SM, Nichols TE (2009) Threshold-free cluster enhancement: Addressing problems of smoothing, threshold dependence and localisation in cluster inference. Neuroimage 44, 83-98.
18. Mori S, Zhang J (2006) Principles of diffusion tensor imaging and its applications to basic neuroscience research. Neuron 51, 527-539.
19. Song SK, Sun SW, Ju WK, Lin SJ, Cross AH, Neufeld AH (2003) Diffusion tensor imaging detects and differentiates axon and myelin degeneration in mouse optic nerve after retinal ischemia. Neuroimage 20, 1714-1722.
20. Sun SW, Liang HF, Trinkaus K, Cross AH, Armstrong RC, Song SK (2006) Noninvasive detection of cuprizone induced axonal damage and demyelination in the mouse corpus callosum. Magn Reson Med 55, 302-308.
21. Dickerson B, Sperling R (2005) Neuroimaging biomark-ers for clinical trials of disease-modifying therapies in Alzheimer's disease. NeuroRx 2, 348-360.
22. Du A, Schuff N, Kramer J, Ganzer S, Zhu X, Jagust W, Miller B, Reed B, Mungas D, Yaffe K (2004) Higher atrophy rate of entorhinal cortex than hippocampus in AD. Neurology 62, 422-427.
23. Lannfelt L, Blennow K, Zetterberg H, Batsman S, Ames D, Harrison J, Masters CL, Targum S, Bush AI, Murdoch R, Wilson J, Ritchie CW, PBT2-201-EURO study group (2008) Safety, efficacy, and biomarker findings of PBT2 in targeting Afj as a modifying therapy for Alzheimer's disease: A phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol 7, 779-786.
24. Vellas B, Andrieu S, Sampaio C, Wilcock G (2007) Disease-modifying trials in Alzheimer's disease: A European task force consensus. Lancet Neurol 6, 56-62.